International journal of cardiology. Congenital heart disease · 2022
Promising PTFE-coating technology of Optimus-CVS™ stents: The new player for congenital heart disease interventions.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Haddad Raymond N, Bonnet Damien, Alsac Jean-Marc, Malekzadeh-Milani Sophie
Аннотация
BACKGROUND: The use of covered stents (CVS) in congenital heart disease (CHD) interventions is increasing but intrinsic properties of commercially available material remain not optimal. The Optimus-CVS™ (AndraTec GmbH, Koblenz, Germany) is a new balloon-expandable, non-premounted, Cobalt-Chromium stent with patented hybrid-cell design, innovative end-free Nano-PTFE sandwich-covering, and competitive deliverability features.
METHODS AND RESULTS: Three patients with CHD received Optimus-CVS during December 2020 at our institution. Indications for CVS implantation were relief of complex aortic recoarctation (57 mm long Optimus-CVS-XL), treatment of intra-stent intimal proliferation in Fontan circulation (48 mm long Optimus-CVS-XXL), and as a bail-out for conduit rupture during pulmonary valve implantation (33 mm long Optimus-CVS-XXL). Procedures were successful and straightforward. Target diameter was achieved and stent shortening was minimal and as expected. No stent failure was recorded on short-term follow-up.
CONCLUSIONS: Optimus-CVS appears to be a reliable high-performing CVS alternative in major CHD situations where CVS are needed. Optimus-CVS offers interesting construction characteristics, smart covering design, and the largest portfolio in terms of diameters and length optimizing lesion care and improving outcomes.
METHODS AND RESULTS: Three patients with CHD received Optimus-CVS during December 2020 at our institution. Indications for CVS implantation were relief of complex aortic recoarctation (57 mm long Optimus-CVS-XL), treatment of intra-stent intimal proliferation in Fontan circulation (48 mm long Optimus-CVS-XXL), and as a bail-out for conduit rupture during pulmonary valve implantation (33 mm long Optimus-CVS-XXL). Procedures were successful and straightforward. Target diameter was achieved and stent shortening was minimal and as expected. No stent failure was recorded on short-term follow-up.
CONCLUSIONS: Optimus-CVS appears to be a reliable high-performing CVS alternative in major CHD situations where CVS are needed. Optimus-CVS offers interesting construction characteristics, smart covering design, and the largest portfolio in terms of diameters and length optimizing lesion care and improving outcomes.